Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 342 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
342 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic pancreatic, non-small cell lung, HR+/HER2− breast, or triple-negative breast cancer—and colorectal cancer during dose escalation only—undergo screening with the FAP-targeted PET tracer [68Ga]Ga-NNS309. Patients with tracer-avid tumors receive [177Lu]Lu-NNS309, a FAP-targeted radioligand that delivers beta radiation to tumor stroma and nearby cancer cells.
ClinicalTrials.gov ID: NCT06562192
TrialFetch AI summary: This trial evaluates a personalized multi-peptide neo-antigen vaccine combined with poly ICLC and the PD-1 inhibitor nivolumab in adult patients with advanced, treatment-resistant stage IIIC-IV melanoma, hormone receptor positive HER2-negative metastatic breast cancer, and stage III-IV non-small cell lung cancer, focusing on safety and immune response.
ClinicalTrials.gov ID: NCT05098210
TrialFetch AI summary: Adults with unresectable or metastatic solid tumors and ECOG performance status 0–1 receive LNCB74 monotherapy in dose-escalation and expansion cohorts. LNCB74 is an investigational B7-H4–targeted antibody–drug conjugate carrying the microtubule-disrupting payload MMAE.
ClinicalTrials.gov ID: NCT06774963
TrialFetch AI summary: Adults with advanced or metastatic CDK4-dependent solid tumors, including HR-positive/HER2-negative breast cancer, receive the investigational oral selective CDK4 inhibitor BGB-43395 alone or with fulvestrant or letrozole. Patients with HR-positive breast cancer generally must have received prior endocrine therapy and a CDK4/6 inhibitor where available, although a separate first-line, CDK4/6 inhibitor–naive cohort is included.
ClinicalTrials.gov ID: NCT06120283
TrialFetch AI summary: Adults with advanced or metastatic breast, non-small-cell lung, gastric/gastroesophageal, or colorectal cancer who have progressed on, cannot tolerate, or cannot access standard therapy receive intravenous DM001 every 3 weeks. DM001 is an investigational bispecific antibody–drug conjugate targeting TROP2 and EGFR that delivers a topoisomerase I inhibitor payload.
ClinicalTrials.gov ID: NCT06475937
TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
TrialFetch AI summary: Adults with previously treated, measurable, unresectable advanced or metastatic solid tumors and ECOG 0–1 receive oral NKT3964 monotherapy, an investigational PROTAC that degrades CDK2. Expansion cohorts focus on HR-positive/HER2-negative breast cancer after CDK4/6 inhibition, CCNE1-amplified platinum-resistant or refractory ovarian cancer, and CCNE1-amplified gastroesophageal adenocarcinoma.
ClinicalTrials.gov ID: NCT06586957
TrialFetch AI summary: Adults with metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive intravenous MDX2001 monotherapy. MDX2001 is an investigational tetraspecific antibody that binds c-MET and TROP2 on tumors while engaging CD3 and providing CD28 costimulation to promote tumor-directed T-cell activity.
ClinicalTrials.gov ID: NCT06239194
TrialFetch AI summary: Adults with previously treated, measurable metastatic HER2-negative breast cancer of a subtype associated with GD2 expression are eligible; confirmed GD2 expression is not required. All receive gemcitabine plus donor-derived, TGF-β-imprinted NK cells intended to enhance tumor killing, with some arms also receiving naxitamab, an anti-GD2 antibody that directs immune attack against GD2-expressing cells.
ClinicalTrials.gov ID: NCT06026657
TrialFetch AI summary: This trial enrolls anthracycline-naive adults with measurable, treatment-refractory soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical or ovarian cancer, or KRAS-mutant pancreatic cancer after at least two prior therapies. Patients receive escalating doses of SPEDOX-6, a doxorubicin formulation encapsulated in human serum albumin that may preferentially deliver drug to tumors with low FcRn expression; FcRn testing is not required.
ClinicalTrials.gov ID: NCT07064018